These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39080620)

  • 1. Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes.
    Zhang X; Jiang J; Xu J; Chen J; Gu Y; Wu G
    BMC Musculoskelet Disord; 2024 Jul; 25(1):601. PubMed ID: 39080620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation.
    Zhang H; Chu Y; Zheng H; Wang J; Song B; Sun Y
    Aging (Albany NY); 2020 Nov; 13(1):525-536. PubMed ID: 33298623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide-1 receptor regulates endoplasmic reticulum stress-induced apoptosis and the associated inflammatory response in chondrocytes and the progression of osteoarthritis in rat.
    Chen J; Xie JJ; Shi KS; Gu YT; Wu CC; Xuan J; Ren Y; Chen L; Wu YS; Zhang XL; Xiao J; Wang DZ; Wang XY
    Cell Death Dis; 2018 Feb; 9(2):212. PubMed ID: 29434185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protective effects of dulaglutide against advanced glycation end products (AGEs)-induced degradation of type Ⅱ collagen and aggrecan in human SW1353 chondrocytes.
    Li H; Chen J; Li B; Fang X
    Chem Biol Interact; 2020 May; 322():108968. PubMed ID: 32004530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice.
    Li P; Tang Z; Wang L; Feng B
    Mol Med Rep; 2017 Sep; 16(3):3421-3426. PubMed ID: 28713911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting receptor for advanced glycation end product (AGE) and oxidative stress involved in the protective effect mediated by glucagon-like peptide-1 receptor on AGE induced neuronal apoptosis.
    Chen S; Yin L; Xu Z; An FM; Liu AR; Wang Y; Yao WB; Gao XD
    Neurosci Lett; 2016 Jan; 612():193-198. PubMed ID: 26679229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1R Agonist Liraglutide Attenuates Inflammatory Reaction and Neuronal Apoptosis and Reduces Early Brain Injury After Subarachnoid Hemorrhage in Rats.
    Tu XK; Chen Q; Chen S; Huang B; Ren BG; Shi SS
    Inflammation; 2021 Feb; 44(1):397-406. PubMed ID: 32951103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways.
    Shi L; Ji Y; Jiang X; Zhou L; Xu Y; Li Y; Jiang W; Meng P; Liu X
    Cardiovasc Diabetol; 2015 Feb; 14():18. PubMed ID: 25855361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced glycation end products induce peroxisome proliferator-activated receptor γ down-regulation-related inflammatory signals in human chondrocytes via Toll-like receptor-4 and receptor for advanced glycation end products.
    Chen YJ; Sheu ML; Tsai KS; Yang RS; Liu SH
    PLoS One; 2013; 8(6):e66611. PubMed ID: 23776688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 receptor regulates receptor of advanced glycation end products in high glucose-treated rat mesangial cells.
    Chang JT; Liang YJ; Leu JG
    J Chin Med Assoc; 2023 Jan; 86(1):39-46. PubMed ID: 36599141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of liraglutide on the proliferation, migration, and osteogenic differentiation of human periodontal ligament cells.
    Pang Y; Yuan X; Guo J; Wang X; Yang M; Zhu J; Wang J
    J Periodontal Res; 2019 Apr; 54(2):106-114. PubMed ID: 30207387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of GPR40 Suppresses AGE-Induced Reduction of Type II Collagen and Aggrecan in Human SW1353 Chondrocytes.
    Gu J; Lin H; Zhang Y; Xu T; Wang T; Xue X; Zhang W; Liu H
    Drug Des Devel Ther; 2020; 14():2371-2379. PubMed ID: 32606604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway.
    Bao Y; Jiang L; Chen H; Zou J; Liu Z; Shi Y
    Cell Physiol Biochem; 2015; 36(6):2366-78. PubMed ID: 26279440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
    Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
    Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide ameliorates oxidized LDL-induced endothelial dysfunction by GLP-1R-dependent downregulation of LOX-1-mediated oxidative stress and inflammation.
    Ying W; Meiyan S; Wen C; Kaizu X; Meifang W; Liming L
    Redox Rep; 2023 Dec; 28(1):2218684. PubMed ID: 37278349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide, a glucagon-like peptide-1 receptor agonist, induces ADAM10-dependent ectodomain shedding of RAGE via AMPK activation in human aortic endothelial cells.
    Baek CH; Kim H; Moon SY; Yang WS
    Life Sci; 2022 Mar; 292():120331. PubMed ID: 35041837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced glycation end products induce the expression of interleukin-6 and interleukin-8 by receptor for advanced glycation end product-mediated activation of mitogen-activated protein kinases and nuclear factor-κB in human osteoarthritis chondrocytes.
    Rasheed Z; Akhtar N; Haqqi TM
    Rheumatology (Oxford); 2011 May; 50(5):838-51. PubMed ID: 21172926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide preserves CD34
    Sforza A; Vigorelli V; Rurali E; Perrucci GL; Gambini E; Arici M; Metallo A; Rinaldi R; Fiorina P; Barbuti A; Raucci A; Sacco E; Rocchetti M; Pompilio G; Genovese S; Vinci MC
    Cardiovasc Diabetol; 2022 Apr; 21(1):51. PubMed ID: 35397526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.
    Sourris KC; Ding Y; Maxwell SS; Al-Sharea A; Kantharidis P; Mohan M; Rosado CJ; Penfold SA; Haase C; Xu Y; Forbes JM; Crawford S; Ramm G; Harcourt BE; Jandeleit-Dahm K; Advani A; Murphy AJ; Timmermann DB; Karihaloo A; Knudsen LB; El-Osta A; Drucker DJ; Cooper ME; Coughlan MT
    Kidney Int; 2024 Jan; 105(1):132-149. PubMed ID: 38069998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: Relevance for bipolar disorder.
    Chaves Filho AJM; Cunha NL; de Souza AG; Soares MV; Jucá PM; de Queiroz T; Oliveira JVS; Valvassori SS; Barichello T; Quevedo J; de Lucena D; Macedo DS
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Apr; 99():109872. PubMed ID: 31954756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.